NewLink Genetics Corporation (NLNK) Stock Is At All-Time

April 16, 2018 - By Patrick Harkless

NewLink Genetics Corporation (NASDAQ:NLNK) Corporate Logo

During Q4 2017 the big money sentiment increased to 1.51. That’s change of 0.29, from 2017Q3’s 1.22. 22 investors sold all, 21 reduced holdings as NewLink Genetics Corporation ratio is positive. 37 grew holdings while 28 funds acquired holdings. Funds hold 23.56 million shares thus 27.79% more from 2017Q3’s 18.44 million shares.
Pacad Investment has invested 0% of its capital in NewLink Genetics Corporation (NASDAQ:NLNK). The United Kingdom-based Barclays Public Ltd Com has invested 0% in NewLink Genetics Corporation (NASDAQ:NLNK). Td Asset Management holds 25,800 shs or 0% of its capital. First Eagle Management has 2.64M shs for 0.05% of their capital. Meeder Asset Management Inc holds 0% or 125 shs in its capital. Amundi Pioneer Asset Management Inc holds 0% or 202,200 shs. Tiverton Asset Mngmt Ltd owns 0.02% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 33,143 shs. Legal And General Gru Public Limited Company reported 7,215 shs. Comml Bank Of Mellon holds 117,179 shs. Clarivest Asset Limited Liability, a California-based fund reported 74,400 shs. Wolverine Asset Mngmt Ltd Liability Co accumulated 2 shs. Zacks Inv reported 15,694 shs. Perceptive Limited Liability Com has 0.12% invested in NewLink Genetics Corporation (NASDAQ:NLNK) for 450,000 shs. Tiaa Cref Inv Limited Com invested in 0% or 143,478 shs. Illinois-based Segall Bryant Hamill Ltd Liability Com has invested 0.02% in NewLink Genetics Corporation (NASDAQ:NLNK).

On Apr, 16, all time low was touched by NewLink Genetics Corporation (NASDAQ:NLNK). Today’s price per share was $4.13. It’s 6.00 % below our $3.88. This setup was reported by Barchart.com. The company has $153.27 million MC. The company’s valuation will be $9.20 million less at $3.88 price target.

NLNK reached $4.125 on during the last trading session after $0.345 change.NewLink Genetics Corporation is downtrending after having declined 65.28% since April 17, 2017. NLNK has 2.15M volume or 93.79% up from normal. NLNK underperformed the S&P 500 by 76.83%.

Analysts await NewLink Genetics Corporation (NASDAQ:NLNK) to report earnings on May, 3. They expect $-0.55 EPS, up 23.61 % or $0.17 from last year’s $-0.72 per share. After $-0.37 actual EPS reported by NewLink Genetics Corporation for the previous quarter, Wall Street now forecasts 48.65 % negative EPS growth.

NewLink Genetics Corporation (NASDAQ:NLNK) Ratings Coverage

In total 5 analysts cover NewLink Genetics (NASDAQ:NLNK). “Buy” rating has 0, “Sell” are 0, while 5 are “Hold”. 0 are bullish. 7 are the (NASDAQ:NLNK)’s analyst reports since November 3, 2017 according to StockzIntelligence Inc. The company rating was downgraded by SunTrust on Monday, April 9. In Friday, November 3 report Jefferies maintained it with “Buy” rating and $25 target. On Monday, April 9 the rating was downgraded by Robert W. Baird to “Neutral”. On Monday, April 9 Cantor Fitzgerald downgraded the shares of NLNK in report to “Neutral” rating. On Friday, April 6 the stock has “Hold” rating by Bank of America. In Friday, April 6 report Jefferies downgraded it to “Hold” rating and $400 target. On Friday, March 2 the firm has “Buy” rating by Bank of America given.

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products for the treatment of cancer.The firm is worth $153.27 million. The Company’s portfolio includes biologic product candidates based on its HyperAcute cellular immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-2, 3-dioxygenase pathway and the tryptophan-2, 3-dioxygenase pathway.Last it reported negative earnings. The firm is developing IDO pathway inhibitors comprising indoximod that is in multiple Phase I and Phase II clinical trials for patients with melanoma, pancreatic cancer, malignant brain tumors, metastatic breast cancer, acute myeloid leukemia, prostate cancer, and non-small cell lung cancer ; and GDC-0919 and atezolizumab (MPDL3280A) that is in Phase Ib clinical trials for patients with locally advanced or metastatic solid tumors.

NewLink Genetics Corporation (NASDAQ:NLNK) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: